JP2018513216A - Ｃａｒ−ｔ細胞の肝動脈注入 - Google Patents

Ｃａｒ−ｔ細胞の肝動脈注入 Download PDF

Info

Publication number
JP2018513216A
JP2018513216A JP2018505578A JP2018505578A JP2018513216A JP 2018513216 A JP2018513216 A JP 2018513216A JP 2018505578 A JP2018505578 A JP 2018505578A JP 2018505578 A JP2018505578 A JP 2018505578A JP 2018513216 A JP2018513216 A JP 2018513216A
Authority
JP
Japan
Prior art keywords
car
cells
cea
subject
infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018505578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513216A5 (enExample
Inventor
シー． カッツ、スティーブン
シー． カッツ、スティーブン
ユンハンス、リチャード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prospect Chartercare Rwmc D/b/a Roger Williams Medical Center LLC
Original Assignee
Prospect Chartercare Rwmc D/b/a Roger Williams Medical Center LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57126310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2018513216(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prospect Chartercare Rwmc D/b/a Roger Williams Medical Center LLC filed Critical Prospect Chartercare Rwmc D/b/a Roger Williams Medical Center LLC
Publication of JP2018513216A publication Critical patent/JP2018513216A/ja
Publication of JP2018513216A5 publication Critical patent/JP2018513216A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018505578A 2015-04-15 2016-04-14 Ｃａｒ−ｔ細胞の肝動脈注入 Pending JP2018513216A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147793P 2015-04-15 2015-04-15
US62/147,793 2015-04-15
PCT/US2016/027582 WO2016168493A1 (en) 2015-04-15 2016-04-14 Hepatic arterial infusion of car-t cells

Publications (2)

Publication Number Publication Date
JP2018513216A true JP2018513216A (ja) 2018-05-24
JP2018513216A5 JP2018513216A5 (enExample) 2019-05-23

Family

ID=57126310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018505578A Pending JP2018513216A (ja) 2015-04-15 2016-04-14 Ｃａｒ−ｔ細胞の肝動脈注入

Country Status (13)

Country Link
US (2) US10471098B2 (enExample)
EP (1) EP3283083A4 (enExample)
JP (1) JP2018513216A (enExample)
KR (1) KR20180021364A (enExample)
CN (1) CN108135937A (enExample)
AR (1) AR104296A1 (enExample)
AU (1) AU2016248090A1 (enExample)
CA (1) CA2982603A1 (enExample)
HK (1) HK1251179A1 (enExample)
IL (1) IL255005A0 (enExample)
MX (1) MX2017013247A (enExample)
TW (1) TWI719019B (enExample)
WO (1) WO2016168493A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531813A (ja) * 2018-08-02 2021-11-25 カイト ファーマ インコーポレイテッドKite Pharma, Inc キメラ抗原受容体療法のｔ細胞の増殖動態及びその使用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3313517B1 (en) 2015-06-24 2023-06-07 The Regents Of The University Of Michigan Histotripsy therapy systems for the treatment of brain tissue
CN107056952A (zh) * 2017-05-10 2017-08-18 常州市第人民医院 Cea.car‑t及其制备与应用
US20200215112A1 (en) * 2017-08-09 2020-07-09 Ctg Pharma Ltd. Chimeric antigen receptor for her2/neu and t-cells expressing same
CN111542545A (zh) 2017-11-03 2020-08-14 索伦托治疗有限公司 Cd38定向嵌合抗原受体构建体
US12276664B2 (en) * 2017-11-30 2025-04-15 Singapore Health Services Pte. Ltd. Method for classifying cancer patients into appropriate hepatocellular carcinoma treatment groups and compounds for treating the patient
SG11202008568WA (en) * 2018-03-09 2020-10-29 Sorrento Therapeutics Inc Dimeric antigen receptors (dar)
AU2019311077B2 (en) * 2018-07-23 2025-05-29 Heidelberg Pharma Research Gmbh Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
WO2020046766A1 (en) * 2018-08-26 2020-03-05 Oaiscell Biotechnologies Method for treating glioblastoma
EP3850004A4 (en) * 2018-09-13 2022-09-07 Nkarta, Inc. NATURAL KILLER CELL COMPOSITIONS AND IMMUNOTHERAPY METHODS FOR TREATMENT OF TUMORS
EP3886737A4 (en) 2018-11-28 2022-08-24 Histosonics, Inc. HISTOTRIPSY SYSTEMS AND METHODS
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP3799881A1 (en) 2019-10-04 2021-04-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Single domain antibodies specifically binding globo - series glycans
EP4067490A4 (en) * 2019-11-25 2024-02-21 Kyoto University T-cell master cell bank
US11813485B2 (en) 2020-01-28 2023-11-14 The Regents Of The University Of Michigan Systems and methods for histotripsy immunosensitization
EP4204084A4 (en) 2020-08-27 2024-10-09 The Regents Of The University Of Michigan ULTRASONIC TRANSDUCER WITH TRANSMIT-RECEIVE CAPABILITY FOR HISTOTRIPSY
EP4217064A4 (en) * 2020-09-22 2024-08-07 TriSalus Life Sciences, Inc. CANCER THERAPY WITH TOLL-LIKE RECEPTOR AGONISTS
CN116685330A (zh) * 2020-09-22 2023-09-01 特萨乐斯生命科学公司 使用toll样受体激动剂的癌症疗法
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022173772A1 (en) * 2021-02-09 2022-08-18 Obi Pharma, Inc. Globo series antigens-binding chimeric antigen receptors and uses thereof
KR20250102047A (ko) 2022-10-28 2025-07-04 히스토소닉스, 인크. 히스토트립시 시스템들 및 방법들
WO2024221001A2 (en) 2023-04-20 2024-10-24 Histosonics, Inc. Histotripsy systems and associated methods including user interfaces and workflows for treatment planning and therapy
WO2025144964A2 (en) * 2023-12-29 2025-07-03 AffyImmune Therapeutics Inc. Novel car constructs and methods of treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165360A1 (en) * 2000-11-30 2002-11-07 Junghans Richard P. Chimeric effector cell receptors against carcinoembryonic antigen
US6676924B2 (en) * 1994-10-05 2004-01-13 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9206440B2 (en) * 2009-01-23 2015-12-08 Roger Williams Hospital Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same
NZ743310A (en) * 2011-03-23 2022-11-25 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
CN104853766A (zh) 2012-10-02 2015-08-19 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
MX378463B (es) 2013-02-26 2025-03-10 Memorial Sloan Kettering Cancer Center Composiciones y usos de las mismas para inmunoterapia.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6676924B2 (en) * 1994-10-05 2004-01-13 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US20020165360A1 (en) * 2000-11-30 2002-11-07 Junghans Richard P. Chimeric effector cell receptors against carcinoembryonic antigen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLIN. CANCER RES., vol. 14, no. 24, JPN6020008064, 2008, pages 8112 - 8122, ISSN: 0004379276 *
CLIN. CANCER RES., vol. 4, JPN6020008068, 1998, pages 2825 - 2832, ISSN: 0004379278 *
CLIN. CANCER RES., vol. 5, JPN6020008066, 1999, pages 3928 - 3941, ISSN: 0004379277 *
CLIN. CNCER RES., vol. 21, no. 14, JPN6020008062, 15 July 2015 (2015-07-15), pages 3149 - 3159, ISSN: 0004379275 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021531813A (ja) * 2018-08-02 2021-11-25 カイト ファーマ インコーポレイテッドKite Pharma, Inc キメラ抗原受容体療法のｔ細胞の増殖動態及びその使用
JP2024016200A (ja) * 2018-08-02 2024-02-06 カイト ファーマ インコーポレイテッド キメラ抗原受容体療法のｔ細胞の増殖動態及びその使用

Also Published As

Publication number Publication date
CN108135937A (zh) 2018-06-08
IL255005A0 (en) 2017-12-31
EP3283083A4 (en) 2018-10-31
TWI719019B (zh) 2021-02-21
TW201708542A (zh) 2017-03-01
EP3283083A1 (en) 2018-02-21
HK1251179A1 (zh) 2019-01-25
WO2016168493A1 (en) 2016-10-20
US20200138863A1 (en) 2020-05-07
MX2017013247A (es) 2018-08-15
AU2016248090A1 (en) 2017-11-02
AR104296A1 (es) 2017-07-12
US10471098B2 (en) 2019-11-12
KR20180021364A (ko) 2018-03-02
US20160303166A1 (en) 2016-10-20
CA2982603A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
US20200138863A1 (en) Hepatic arterial infusion of car-t cells
Daei Sorkhabi et al. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
Ahmed et al. Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma
JP2022113883A (ja) 抗ｂｃｍａ ｃａｒ ｔ細胞組成物
Vauleon et al. Overview of cellular immunotherapy for patients with glioblastoma
Feldman et al. Adoptive cell therapy—tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors
Avila et al. New therapies for hepatocellular carcinoma
Wu et al. B7H6-specific bispecific T cell engagers lead to tumor elimination and host antitumor immunity
Yu et al. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma
Wang et al. Adoptive cell therapy: a novel and potential immunotherapy for glioblastoma
CN118546961A (zh) 用于细胞治疗的组成型活性细胞因子受体
US6805869B2 (en) Cellular vaccines and immunotherapeutics and methods for their preparation
JP2018521069A (ja) 腹膜癌を治療するための組成物及び方法
US20220347214A1 (en) Compositions and methods for tcr reprogramming using fusion proteins
Tesfaye et al. Adoptive cell therapy in treating pediatric solid tumors
JP2025507919A (ja) Ｇｄ２キメラ抗原受容体及びその使用
Xu et al. Enhanced cellular therapy: revolutionizing adoptive cellular therapy
Nagasawa et al. Passive immunotherapeutic strategies for the treatment of malignant gliomas
WO2022020720A9 (en) Compositions and methods for treating cancer
US20240058447A1 (en) Use of fusion constructs for il-2 independent t cell therapy
Bogacz et al. Modern immunotherapy using CAR-T cells in haemato-oncology and solid tumors
US20230065936A1 (en) Compositions and methods for treating cancer
WO2024055339A1 (zh) 用于制备和扩增通用型人源化抗cd19 car-nk细胞的方法及其用途
Sanders Modulation of the Immune Response as a Potential Therapeutic for Glioblastoma
Bosch Approaches to improve chimeric antigen receptor T-cell therapy in solid tumors. Focusing on current CAR models and the tumor microenvironment.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201104